Chi­nese in­vestors wa­ger $105M on an IPO-bound biotech look­ing to push RNAi as main­stream can­cer ther­a­py

Short­ly af­ter Sir­naomics brought in a $47 mil­lion Se­ries C for its small in­ter­fer­ing RNA pipeline last year, Patrick Lu — the founder, pres­i­dent and CEO — was asked to out­line the sci­en­tif­ic ad­vances that will be nec­es­sary to make bet­ter drugs out of RNA tech.

“The next step in the evo­lu­tion of RNAi as a lead­ing ther­a­peu­tic will be the abil­i­ty to safe­ly tar­get or­gans out­side the liv­er such as lung, brain, etc,” he had of­fered. “This will rev­o­lu­tion­ize dis­ease treat­ments if the in­dus­try can demon­strate sim­i­lar da­ta sets for non-liv­er tar­gets as we have seen in liv­er-based dis­eases.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER